BioNxt Solutions Inc. is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed.
BioNxt Solutions Inc. is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed.